Neurotoxicity of Intrathecally Administered Fentanyl in a Rat Spinal Model

Pain Medicine

Volumn 12, Issue 5, 2011, Pages 717-725

  Fukushima, Sayano ^a   Takenami, Tamie ^a   Yagishita, Saburo ^b   Nara, Yoshihiro ^a   Hoka, Sumio ^a   Okamoto, Hirotsugu ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAGAWA REHABILITATION CENTER   (Japan)

Author keywords

Inflammatory Mass; Intrathecally Administered Fentanyl; Neurotoxicity; Rat Spinal Model

Indexed keywords

FENTANYL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APNEA; ARACHNOID; ARTICLE; BRADYCARDIA; CATHETER; CAUDA EQUINA; CONTROLLED STUDY; DORSAL ROOT; HAIR LOSS; HEAT; HISTOPATHOLOGY; INFLAMMATION; LATENT PERIOD; MALE; NERVE INJURY; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; PAIN; PERCEPTIVE THRESHOLD; RAT; SPINAL CORD; TISSUE INJURY; VENTRAL ROOT; WALKING;

EID: 79955897523     PISSN: 15262375     EISSN: 15264637     Source Type: Journal    
DOI: 10.1111/j.1526-4637.2011.01084.x     Document Type: Article

References (15)

1. Thimineur MA, Kravitz E, Vodapally MS. Intrathecal opioid treatment for chronic non-malignant pain: A 3-year prospective study. Pain 2004;109:242-9.
2. Yaksh TL, Hassenbusch S, Burchiel K, etal. Inflammatory masses associated with intrathecal drug infusion: A review of preclinical evidence and human data. Pain Med 2002;3:300-12.
3. Deer T, Krames ES, Hassenbusch S, etal. Management of intrathecal catheter-tip inflammatory masses: An updated 2007 consensus statement from an expert panel. Neuromodulation 2008;11:77-91.
4. Waara-Wolleat KL, Hildebrand KR, Stewart GR. A review of intrathecal fentanyl and sufentanil for the treatment of chronic pain. Pain Med 2006;7:251-9.
5. Yaksh TL, Rudy TA. Chronic catheterization of the spinal subarachnoid space. Physiol Behav 1976;17:1031-6.
6. Takenami T, Yagishita S, Asato F, Hoka S. Neurotoxicity of intrathecally administered tetracaine commences at the posterior roots near entry into the spinal cord. Reg Anesth Pain Med 2000;25:372-9.
7. Bailey PL, Egan TD, Stanley TH. Intravenous opioid anesthetics. In: Miller RD, ed. Anesthesia, 5th edition. Philadelphia, PA: Churchill Livingstone; 2000:273-376.
8. Yaksh TL, Noueihed RY, Durant PAC. Studies of the pharmacology and pathology of intrathecally administered 4-anilinopiperidine analogues and morphine in the rat and cat. Anesthesiology 1986;64:54-66.
9. Sabbe MB, Grafe MR, Mjanger E, etal. Spinal delivery of sufentanil, alfentanil and morphine in dogs: Physiologic and toxicologic investigations. Anesthesiology 1994;81:899-920.
10. Rawal N, Nuutinen L, Raj PP, etal. Behavioral and histopathologic effects following intrathecal administration of butorphanol, sufentanil, and nalbuphine in sheep. Anesthesiology 1991;75:1025-34.
11. Allen JW, Horais KA, Tozier NA, Yaksh TL. Opiate pharmacology of intrathecal granulomas. Anesthesiology 2006;105:590-8.
12. Gradert TL, Baze WB, Satterfield WC, etal. Safety of chronic intrathecal morphine infusion in a sheep model. Anesthesiology 2003;99:188-98.
13. Takenami T, Yagishita S, Murase S, etal. Neurotoxicity of intrathecally administered bupivacaine involves the posterior roots/posterior white matter and is milder than lidocaine in rats. Reg Anesth Pain Med 2005;30:464-72.
14. Auroy Y, Benhamou D, Bargues L, etal. Major complications of regional anesthesia in France: The SOS regional anesthesia hotline service. Anesthesiology 2002;97:1274-80.
15. Deer TR, Smith HS, Cousins M, etal. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician 2010;13:E175-213.